Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Breast 2

Conditions

Prostatic Neoplasms 2Hot Flashes 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 284Gemcitabine 273enzalutamide 254Radiotherapy 251Nivolumab 247Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 197Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 98cabozantinib 97abiraterone 97Sorafenib 97atezolizumab 96Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × fezolinetant × Genitourinary × Clear all
NCT07568236 2026-05-05

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

Chinese University of Hong Kong

Phase 2 Not yet recruiting
54 enrolled
Genitourinary

Prostatic Neoplasms

NCT06972875 2026-02-05

FLASH

University of Vermont

Phase 2 Recruiting
32 enrolled
Genitourinary

Prostatic Neoplasms, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡